FDA Brief

Warning letters Devices

FDA warning letter to

Trexo Robotics Holdings Inc.

High riskIssued Feb 7, 2024Posted Jun 4, 2024"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality"

FDA warns Trexo Robotics over unapproved robotic gait-training legs for children and design-control gaps at its Canadian plant.

What happened

FDA inspected Trexo Robotics Holdings Inc. in Mississauga, Ontario, Canada from June 3 through June 5, 2023, and also reviewed the firm's website on October 5, 2023. FDA concluded the Trexo Home and Trexo Plus devices are marketed for a new intended use - helping children with disabilities walk and stand - without an approved premarket approval (PMA) application or investigational device exemption (IDE), and without a 510(k) premarket notification. The inspection also found the firm's quality system procedures did not meet the Quality System regulation (21 CFR Part 820).

What FDA found

  1. The firm sells the device for a use outside the exempt category and without an approved PMA or IDE, which makes it adulterated.

    Section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)
  2. The firm began commercial distribution without sending FDA a 510(k) premarket notification, which makes the device misbranded.

    Section 502(o) of the Act, 21 U.S.C. § 352(o); 21 CFR 807.81
  3. Design control procedures did not ensure the design process was followed or that validation on initial production units was done and documented.

    21 CFR 820.30(a)
  4. Procedures did not ensure that processes which cannot be fully verified by later inspection and testing, such as the circuit board and motor tests, were validated.

    21 CFR 820.75(a)
  5. Corrective and preventive action procedures did not require review of all quality data sources, such as nonconformance reports.

    21 CFR 820.100(a)(1)
  6. Complaint procedures allowed complaints to be handled as feedback, so they were not checked for reporting to FDA, and some complaint investigations were not documented.

    21 CFR 820.198(a)

What FDA wants

FDA tells the firm to stop activities that misbrand or adulterate the Trexo devices, including commercial distribution for the uses described. The firm must reply in writing with the specific corrections, corrective actions, supporting documentation and, if work is ongoing, a timetable.

Who should pay attention

  • pediatric rehabilitation clinics and therapists considering robotic gait devices
  • U.S. distributors and resellers of foreign-made medical devices
  • quality teams at device startups that rely on an exempt classification
  • contract manufacturers building powered rehabilitation hardware

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  4. Tides Medical LLC

    FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

    High risk